Biomerica Inc (BMRA)
NASDAQ:BMRA
Top Page
Biomerica
(NASDAQ:BMRA)
Select Model
Select Model
Rating:47Neutral
Price Target:
$2.00
▼(-30.56% Downside)
Action:UpgradedDate:01/15/26
The score is primarily constrained by weak financial performance—shrinking revenue, very low margins, sizable losses, and ongoing free-cash-flow burn—despite improving loss/cash-burn trends and low leverage. Technical indicators are mildly supportive in the near term, but valuation remains challenged due to negative earnings and no dividend data.
Positive Factors
Diversified Sales Channels
A mixed go-to-market model (direct plus distributors) supports broader market access and recurring consumable sales. Over the medium term this reduces customer concentration risk, enables leverage of distributor networks for scaling, and smooths demand swings across channels.
Negative Factors
Declining Revenue and Weak Margins
Sustained revenue decline and very low gross margins indicate the core product portfolio lacks scale or pricing power. Persistent negative margins constrain the ability to reinvest in sales and R&D and make profitable growth difficult to achieve without structural changes to cost or product mix.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified Sales Channels
A mixed go-to-market model (direct plus distributors) supports broader market access and recurring consumable sales. Over the medium term this reduces customer concentration risk, enables leverage of distributor networks for scaling, and smooths demand swings across channels.
Read all positive factors
Biomerica (BMRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.43M
Dividend YieldN/A
Average Volume (3M)190.48K
Price to Earnings (P/E)―
Beta (1Y)2.04
Revenue Growth-20.05%
EPS Growth41.89%
CountryUS
Employees64
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.45
Shares Outstanding3,020,067
10 Day Avg. Volume453,881
30 Day Avg. Volume190,481
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.71
Price to Sales (P/S)1.32
P/FCF Ratio-1.81
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue0.96
Enterprise Value/Gross Profit17.06
Enterprise Value/Ebitda-1.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biomerica Business Overview & Revenue Model
Company Description
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits ...
How the Company Makes Money
Biomerica makes money primarily by selling diagnostic products (e.g., in vitro diagnostic test kits and related supplies) through a combination of direct sales and distributor-based channels to clinical laboratories, hospitals, and other healthcar...
Biomerica Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.46M | 5.31M | 5.42M | 5.34M | 18.87M | 7.20M |
| Gross Profit | 250.00K | 498.00K | 611.00K | 446.00K | 2.98M | 366.29K |
| EBITDA | -3.68M | -4.74M | -5.99M | -6.87M | -3.94M | -7.06M |
| Net Income | -4.03M | -4.97M | -5.98M | -7.14M | -4.53M | -7.45M |
Balance Sheet | ||||||
| Total Assets | 6.03M | 5.95M | 9.25M | 14.45M | 11.37M | 11.82M |
| Cash, Cash Equivalents and Short-Term Investments | 2.54M | 2.40M | 4.17M | 9.72M | 5.92M | 4.20M |
| Total Debt | 284.00K | 458.00K | 785.00K | 1.08M | 1.38M | 1.62M |
| Total Liabilities | 1.60M | 1.84M | 2.66M | 2.73M | 3.05M | 2.59M |
| Stockholders Equity | 4.43M | 4.11M | 6.59M | 11.72M | 8.32M | 9.23M |
Cash Flow | ||||||
| Free Cash Flow | -2.93M | -3.88M | -5.48M | -5.55M | -650.87K | -5.55M |
| Operating Cash Flow | -2.96M | -3.84M | -5.36M | -5.47M | -480.53K | -5.25M |
| Investing Cash Flow | 0.00 | -37.00K | -115.00K | -78.00K | -170.34K | -295.58K |
| Financing Cash Flow | 3.13M | 2.11M | -81.00K | 9.39M | 2.39M | 1.11M |
Biomerica Technical Analysis
Neutral
2.88
Price Trends
2.27
Negative
2.38
Negative
2.76
Negative
Market Momentum
-0.04
Negative
49.81
Neutral
69.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMRA, the sentiment is Neutral. The current price of 2.88 is above the 20-day moving average (MA) of 2.07, above the 50-day MA of 2.27, and above the 200-day MA of 2.76, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 49.81 is Neutral, neither overbought nor oversold. The STOCH value of 69.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BMRA.
Biomerica Risk Analysis
Biomerica disclosed 32 risk factors in its most recent earnings report. Biomerica reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Biomerica Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $14.71M | -0.43 | 20.03% | ― | -99.28% | -46.17% | |
47 Neutral | $6.43M | -1.24 | -84.30% | ― | -20.05% | 41.89% | |
46 Neutral | $1.53M | -14.23 | -476.74% | ― | -5.19% | -0.81% | |
40 Underperform | $7.87M | -1.29 | -220.42% | ― | -41.03% | 35.71% | |
| ― | $5.01M | -0.38 | -228.82% | ― | ― | 63.87% |
* Healthcare Sector Average
BMRA
Biomerica
2.13
-3.25
-60.41%
SSKN
Strata Skin Sciences
0.26
-2.46
-90.44%
PAVM
PAVmed
9.83
-12.95
-56.85%
HSCS
Heart Test Laboratories, Inc.
2.47
-0.57
-18.75%
AMIX
Autonomix Medical, Inc.
0.44
-1.57
-78.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.